



CELLIANT®

ENHANCE YOUR LIFE.

WWW.IRONMANMATTRESS.CA



CELLIANT®

ENHANCE YOUR LIFE.



CELLIANT®

THE WORLD'S FIRST RESPONSIVE TEXTILE

WITH CLINICALLY PROVEN BENEFITS
TO THE HUMAN BODY.

Celliant® has been proven in clinical tests to reduce pain, increase oxygen levels, and help balance body temperature. Each of these results can have added benefits including faster healing, increased performance, better-quality sleep, and improved overall wellness all of which can help alleviate the symptoms of arthritis and peripheral vascular disease often associated with diabetes.

The key to Celliant® lies in it's ability to absorb and store the electromagnetic (energy) emissions from the human body and release them where they are reabsorbed into the skin and deep muscle tissue. In the deep muscle tissue they act as catalysts for natural, biological processes resulting in enhanced oxygen levels and more balanced body temperature during sleep, rest or physical activity.

ENHANCE YOUR LIFE.

HOW CELLIANT® WORKS:



1

Celliant® fibers are created from natural minerals and embedded into polyester fibers.

2

Celliant® fibers absorb energy from the body.

3

Celliant® converts the energy into a form usable by the body.

4


Celliant® recycles this energy back to the body.

5

This recycled energy triggers natural chemical reactions in the body.

6

These reactions result in increased blood flow and oxygenation to the tissue.





Australian Government

Department of Health
Therapeutic Goods Administration

Australian Register of Therapeutic Goods Certificate

Issued to

Perform-Tex Australasia

for approval to supply

Perform-Tex Australasia - Cover, mattress, <specify>

ARTG Identifier 220932
ARTG Start date 8/03/2014
Product Category Medical Device Included Class 1
GMDN 12467
GMDN Term Cover, mattress, <specify>
Intended Purpose A material used as a physical barrier on a mattress, the construction of the cover combines a special therapeutic feature, the inclusion of Celliant fibres are intended to absorb the body's electromagnetic energy emissions (both heat and infrared) and return infrared energy back to the body to help increase blood flow, circulation and tissue oxygenation. This is a reusable device.

| Manufacturer Details | Address | Certificate number(s) |
|----------------------|--|-----------------------|
| Hologenix LLC | 1112 Montana Avenue Santa Monica, CA, 90403 United States Of America | |

ARTG Standard Conditions

The above Medical Device Included Class 1 has been entered on the Register subject to the following conditions:

- The automatic conditions applicable to the inclusion of all kinds of medical devices in the Register are as specified in section 41FN of the Therapeutic Goods Act 1989.,
- The standard conditions that are imposed under section 41FO of the Therapeutic Goods Act 1989 when kinds of medical devices are included in the Register are as set out in the following paragraphs.,
- For a medical device included in the Register under Chapter 4 and imported into Australia, the Sponsor must ensure that information about the Sponsor is provided in such a way as to allow the sponsor to be identified.,
- Each sponsor shall retain records of the distribution of all of the sponsor's medical devices included in the Register under Chapter 4. In the case of records relating to a Class AIMD medical device, Class III medical device, or Class IIb medical device that is an implantable medical device, the distribution records shall be retained for a minimum period of 10 years. In the case of records relating to any other device, the distribution records shall be retained for a minimum period of 5 years.,
- The sponsor of a medical device included in the Register under Chapter 4 shall keep an up to date log of information of the kind specified in Regulation 5.8.,
- It is a condition of inclusion in the ARTG that the sponsor of a medical device that is an AIMD, Class III or implantable Class IIb provides three consecutive annual reports to the Head of the Office of Product Review, Therapeutic Goods Administration following inclusion of the device in the ARTG (as specified in 5.8 of the regulations). Annual reports are due on 1 October each year. Reports should be for the period 1 July to 30 June. The first report following the date of inclusion in the ARTG must be for a period of at least six months but no longer than 18 months. Subsequent reports are to be provided on 1 October for a further 2 years. The annual report must include all complaints and adverse events received by the manufacturer relating to problems with the use of the device that have been received by them over the year. For orthopaedic implant prosthesis that have been re-classified from Class IIb to Class III medical devices, annual report information must be submitted if the device meets either of the following criteria: I.The device was subject to a TGA application audit based on revision rate when the device transitioned from Class IIb to Class III; and/or II.No devices were supplied to the Australian marketplace before 30 June 2012. As per the standard automatic condition, annual reports should be submitted each year for the first three years of inclusion as a Class III medical device on the ARTG.,
- Where a medical device included in the Register, contains a substance which is included in the Fourth

HOLOGENIX, LLC SCIENCE ADVISORY BOARD (SAB) FOR CELLIANT TECHNOLOGY

Hologenix formed the Science Advisory Board in 2011 to further establish itself as the leader in responsive textile technologies. Hologenix works in partnership with the SAB to identify, design and execute rigorous clinical studies to further validate and substantiate our significant claims. The appointments include Dr. Michael Hamblin (Photobiology), Dr. Shimon Weiss (Nanotechnology), Dr. Christopher Drake (Sleep Medicine), and Dr. Lawrence Lavery (Diabetes and Wound Care).

Dr. Hamblin (Photobiology) - With over 30 years of experience, Dr. Hamblin is the Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital and is an Associate Professor of Dermatology at Harvard Medical School. He is also a member of the affiliated faculty of the Harvard-MIT Division of Health Science and Technology. For the past seven years, Dr. Hamblin has chaired an annual conference at SPIE Photonics West entitled "Mechanisms for Low-Light Therapy."



Dr. Weiss (Nanotechnology) - Dean M. Willard Chair in Chemistry and Professor of Chemistry and Biochemistry, Physical Chemistry, and Physiology and a member of the California NanoSystems Institute at UCLA. He has been a scientific researcher for over 20 years, both in and out of the university. The Weiss lab has worked on ultrasensitive single molecule spectroscopy methods for over 15 years, and was the first to introduce the single molecule FRET method and were among the first to introduce quantum dots to biological imaging.

Dr. Drake (Sleep Medicine) - Chairman of the National Sleep Foundation, Bioscientific Principal Investigator at the Henry Ford Hospital Sleep Disorders Research Center, in addition to being associate Professor of Psychiatry and Behavioral Neurosciences at the School of Medicine, Wayne State University. Along with authoring over 150 articles, reviews and abstract in his field, Dr. Drake serves on the editorial board of various sleep behavioral sleep field journal.



Dr. Lavery (Diabetes and Wound Care) - Currently a professor of surgery at University of Texas Southwestern Medical Center, Dr. Lavery is also the Vice Chair of Medical Affairs, Chronic Disease Specialists. He has served on the editorial board for Diabetes Care and has been published in more than 140 peer-reviewed publications. He is also the former chair of the American Diabetes Association Foot Care Council.

CELLIANT TECHNOLOGY / SUMMARY OF CLINICAL STUDIES

HOLOGENIX, LLC
2014

| DATE | TITLE | PRINCIPAL INVESTIGATOR | SPONSORING INSTITUTION | SUMMARY RESULTS | STATUS | NUMBER OF SUBJECTS |
|-----------|---|---|--|--|---------------------|--------------------|
| 2013-2014 | A Single Center Prospective Comparative Study to Evaluate the Performance of a Upper Torso Garment Containing 100% Celliant Fibers that Emits Far Infrared (FIR) from Ceramic Particles Contained Within the Fibers in Healthy Subjects | Dr. Ian Gordon | Hologenix, LLC | An average TcPO2 gain of over 8% across 71% of all subjects with clinically significant differences at a 99% degree of confidence. | Pending Publication | 153 |
| 2012 | Impacts of Subjects Socks with the Application of Celliant™ Technical Fibers on Transcutaneous Oxygen Pressure | Dr. Li Shaojing | Academy of Chinese Sciences | An average TCPO2 gain of 17% in subjects foot. | Complete | 100 |
| 2012 | Effect of Celliant Materials on Pain and Strength with Chronic Elbow and Wrist Pain | Dr. Ian Gordon | University of CA, Irvine Long Beach Veteran's Affairs Medical Center | Pain reduced and 10% increase in grip strength | Pending Publication | 70 |
| 2011 | Influence of Celliant on Athlete Performance & Recovery | Dr. Darren Stefanyshyn / Dr. Jay Worobets | University of Calgary Human Performance Laboratory | Subjects consumed 1.8% less oxygen to accomplish the same amount of work. | Published | 12 |
| 2008-2011 | Double blind, placebo controlled, crossover trial on the effect of Optically Modified Polyethylene Terephthalate Fiber mattress covers on sleep disturbances in patients with chronic back pain | Dr. Marcel Hungs / Dr. Annabel Wang | University of CA, Irvine Medical Center, Orange CA | Nighttime awakenings, sleep quality, and sleep efficiency improved. Findings significant enough to expand study. | Abstract | 12 |
| 2009 | Effect of Garment with 42% Celliant™ fiber on TCP02 Levels and Grip Strength in Healthy Subjects | Dr. Ian Gordon | University of CA, Irvine Long Beach Veteran's Affairs Medical Center | An average TCPO2 gain of 7% and an average gain in grip strength of 12%. | Abstract | 51 |
| 2009 | Effect of Optically Modified Polyethylene Terephthalate Fiber Socks on Chronic Foot Pain | Dr. Ian Gordon / Dr. Robyn York | University of CA, Irvine Medical Center, Orange CA | Statistically significant reduction of pain and improved comfort for subjects. | Published | 55 |

CELLIANT TECHNOLOGY / SUMMARY OF CLINICAL STUDIES CONTINUED

HOLOGENIX, LLC



| DATE | TITLE | PRINCIPAL INVESTIGATOR | SPONSORING INSTITUTION | SUMMARY RESULTS | STATUS | NUMBER OF SUBJECTS |
|------|---|------------------------|--|---|----------|--------------------|
| 2005 | Celliant Study of Thirteen Healthy Subjects | Dr. Graham McClue | University of Texas A&M Houston, Texas | A average increase in TCPO2 levels from 10% to 24%. | Abstract | 13 |
| 2003 | Improving Blood Flow with Celliant in the Hands and Feet of High-Risk Diabetics | Dr. Lawrence Lavery | Loyola University Chicago, Chicago, IL | An average increase in TCPO2 levels from 12% in the hands and 8% in the feet. | Abstract | 20 |

CELLIANT TECHNOLOGY / SUMMARY OF CLINICAL STUDIES UNDER DEVELOPMENT

| DATE | TITLE | PRINCIPAL INVESTIGATOR | SPONSORING INSTITUTION | SUMMARY RESULTS | STATUS | NUMBER OF SUBJECTS |
|------|--|--------------------------------------|--|-----------------|-----------|--------------------|
| 2013 | The Sleep Effects of a Mattress Cover Made with Optically Vaso-Active Fibers | Dr. Tom Roth / Dr. Christopher Drake | Henry Ford Hospital, Detroit MI | Pending | In Design | TBD |
| 2013 | Biological Basis of Wound Healing with Celliant Wound Dressing | Dr. Lawrence Lavery | University of Texas Southwestern Medical Center at Dallas | Pending | In Design | TBD |
| 2013 | The use of quantum dots as a biomarker for increased circulation | Dr. Shimon Weiss | UCLA dept. of Chemistry and Biochemistry | Pending | In Design | N/A |
| 2013 | Celliant fabric used to protect cells from oxidative stress | Dr. Michael Hamblin | Wellman Center for Photomedicine at Massachusetts General Hospital | Pending | In Design | N/A |



2003 – OXYGEN INCREASE IN DIABETIC SUBJECTS

- Performed by Lawrence A. Lavery, DPM, MPH, an associate professor in the department of orthopedic surgery and rehabilitation at Loyola University Medical Center and Hines Veterans Administration Hospital in Chicago.
- Tested TCPO₂ (how much oxygen reaches the surface of the skin) in the hands and feet.
- Study of 20 diabetic subjects wearing Celliant™ gloves and stockings vs. placebo garments.
- Within one hour subjects showed on average a 13.6% improvement in their hands with 100% Celliant™ gloves and an 8% improvement in their feet with 50% Celliant™ stockings.



2005 – OXYGEN INCREASE IN HEALTHY SUBJECTS



- Performed by Graham M. McClue, Ph. D., a researcher with Hyperbaric Treatment & Training Services Ltd., an independent research facility in Houston, Texas.
- Tested TCPO₂ in the hands and feet.
- Double blind study of 13 healthy subjects wearing Celliant™ gloves and stockings vs. placebo garments.
- Within one hour subjects showed an increase of oxygen levels by 10% to 24%.



2008 - DIABETIC PAIN STUDY




- Performed by Dr. Ian Gordon, M.D., Ph.D. at University of California Irvine Medical Center, Director of the University of California Wound Clinic, Associate Clinical Professor of Surgery at the University of California, Irvine and Chief of the Vascular Surgery Section at the VA Long Beach Healthcare System.
- Single-center, prospective, double-blind, randomized trial approved by the institutional review board with test subject receiving either Celliant™ or control socks.
- 55 Subjects filled out McGill Short Form Pain Surveys—an industry accepted scale for measuring pain relief that is used in FDA trials for pain relief medications—for two consecutive weeks to measure pain.
- Participants received a 2.7x greater reduction in pain for participants wearing products enhanced with Celliant™ versus those wearing placebo products.




2008 – OXYGENATION STUDY



- Ian Gordon, M.D., Ph.D. F.A.C.S., Clinical Professor of Surgery, UC Irvine.
- 24 healthy volunteers wore both Celliant™ and placebo garments for 90 minutes.
- Subjects were tested for skin temperature, grip strength and TCPO₂ levels.
- Overall 8% increase in oxygen levels and 12% increase in grip strength.




CELLIANT™ IMPROVES SLEEP



Sleep efficiency with a placebo

- Significant nocturnal awakenings
- 67% Sleep efficiency



Sleep efficiency with Celliant™

- Zero nocturnal awakenings
- 95% Sleep efficiency



THE EFFECTS OF CELLIANT™



EFFECTS OF CELLIANT™ ON TEMPERATURE LEVELS IN THE BODY

The diagram features a vertical color gradient bar on the left labeled 'Body Temperature Range', with 'Balanced' at the top (pink) and 'Unbalanced' at the bottom (blue). Two human silhouettes are shown. The first, labeled 'Before', has a diagonal arrow from the core to the extremities, with text: 'Before Body temperature differential between core and extremities.' The second, labeled 'After', has a more horizontal arrow, with text: 'After More even distribution of body temperature with Celliant.'

Celliant™ has been proven in clinical testing to help balance body temperature. With Celliant™, your body maintains more balanced temperature levels, aiding in comfort and well-being.



WHAT RESEARCHERS ARE SAYING ABOUT CELLIANT™



"It's important to note that properly controlled clinical trials have shown a positive effect from wearing clothing enhanced with Celliant™. Frankly, as a skeptic, I was surprised at the results and am excited to conduct additional trials."

● **Dr. Ian Gordon, MD, PhD**

Director of the University of California Wound Clinic, Associate Clinical Professor of Surgery at the University of California, Irvine and Chief of the Vascular Surgery Section at the VA Long Beach Healthcare System

"This study shows a significant increase in blood flow in the skin. This improvement might be enough to take patients from being symptomatic to asymptomatic, which for patients that are taking 10 or 15 drugs, to be able to wear a garment with no negative side effects is a tremendous advantage."

● **Dr. Lawrence A. Lavery, DPM, MPH**

Associate Professor, Department of Orthopedic Surgery and Rehabilitation, Loyola University Medical Center & Hines Veterans Administration Hospital, Chicago, Illinois

"There are a number of benefits that will come out of wearing this product. In the athlete, it will increase oxygen metabolism rates, therefore enhancing performance. It will also aid recovery of people that don't exercise very often. Most often you exercise and become stiff. This will help to eliminate the stiffness. In the diabetic population, it will increase oxygen at the surface or oxygen to wounds and eventually the wounds will heal on a quicker basis."

● **Dr. Graham McClue, PhD**

Research Director, Hyperbaric Treatment & Training Center, Houston, Texas

"The first two participants reported a subjective improvement of their sleep with the use of the active garment mattress cover... In addition, objective sleep recordings in both subjects showed improved sleep efficiency (more sleep while in bed), a decreased wake after sleep onset time (less total night time awake after initial sleep onset), and an overall reduced number of nocturnal awakenings"

● **Dr. Marcel Hungs, MD, PhD**

Assistant Clinical Professor, Department of Neurology, University of California, Irvine
Director, Center for Sleep Medicine



WHAT CONSUMERS ARE SAYING ABOUT CELLIANT™



"I was having a lot of sleeping problems due to breaking my back in a motocross accident about 5 years ago. A friend suggested I try a mattress pad with Celliant™. Ever since, I almost sleep too well. I am a firm believer in this product and recommend it to everyone!"

● **Donny Emler Jr. aka "LIL D", FMF Racing**

"I have been a type II diabetic for 15 years and recently neuropathy has been affecting my legs and feet. I tried a number of different support hose and have not been satisfied with their performance. In many cases they restricted the blood flow and ended up increasing the pain. Your socks have been fantastic. I seem to get the support that I need without the restrictions. They not only help with the numbness but provide the support that I need to assist me in walking."

● **Frank S. Chase, Nashua, New Hampshire**

"During the 2005 Toronto Marathon, I wore Celliant™ running socks and had zero problems with my feet... As it happened, I ended up seeing my doctor a few days later for my annual physical. He was amazed that my feet didn't show any signs of blistering, swelling, bruising etc."

● **Andrew Wells, Real Estate Broker and Marathon Runner, Toronto, Canada**

"In "Terminator 3: Rise of the Machines," I play the most powerful machine yet, opposite Arnold Schwarzenegger. Powerful machines may be impervious to pain, but people aren't, so I wore Celliant™ socks throughout a difficult and grueling shooting schedule, and it helped me recover quickly from exertion."

● **Kristanna Loken, Actress**

